Wedbush Maintains Outperform on United Therapeutics, Raises Price Target to $308
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Liana Moussatos maintains an Outperform rating on United Therapeutics (NASDAQ:UTHR) and raises the price target from $307 to $308.
November 02, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Therapeutics' price target has been raised from $307 to $308 by Wedbush, which maintains an Outperform rating on the stock.
The raised price target indicates that the analyst sees further upside potential for the stock, which could lead to positive investor sentiment and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100